Roche’s Evrysdi Approved For SMA, Priced Below Competitors

Oral drug will rival Biogen, Novartis therapies

 
• By Mandy Jackson
FDA Approved text, inscription, phrase is written in a notebook that lies on a wooden table and a pen. Business concept.
Evrysdi is the first oral, but third disease-modifying therapy for SMA • Source: Shutterstock

More from New Products

More from Scrip